In another display of monoclonal antibodies' appeal to drug developers, Maryland-based Humab Genome Sciences announced that it will team up with Xencor on drug development. Xencor uses its XmAb technologies--which humanizes antibodies--to enhance the pharmacologic properties of monoclonal antibodies developed by HGS that specifically target antigens discovered by HGS. Xencor gains an upfront payment and could earn additional payments including development and commercial milestones, and royalties. Further financial details were not disclosed. Xencor was a 2005 Fierce 15Â company.
- see this releaseÂ for more